Maimonides Medical Center

NOTTINGHAMSHIRE, United Kingdom, Oct. 8, 2024 /PRNewswire/ -- Chalice Medical, Inc, is thrilled to announce that Maimonides Medical Center in Brooklyn, New York, has become the first hospital in the United States to adopt the innovative CMO8 oxygenator. This groundbreaking device was specifically designed and developed harnessing years of experience and dedication to life extending technologies. The CMO8 oxygenator offers several features that set it apart from traditional devices. These include a unique blend of performance characteristics - large surface area, innovative flow path, and unique air handling capabilities - all in one design. The blood outlet port has also been strategically placed to maximize membrane contact, which leads to optimized gas transfer efficiency and excellent air handling properties. "We are honored that Maimonides Medical Center has chosen to provide its patients with our technology," said Philip Bousfield, Managing Director at Chalice Medical, LTD. "The CMO8 oxygenator represents a significant advancement for us, and we believe it will positively support patient outcomes in the US". Maimonides Medical Center is a renowned healthcare institution with a long history of providing cutting-edge medical care. The hospital's decision to adopt the CMO8 oxygenator underscores its commitment to providing the best possible care for its patients. About Chalice Medical Chalice Medical Inc. is the exclusive US distributor for Chalice Medical Ltd, a UK-based medical device manufacturer specializing in products for extracorporeal life support (ECLS). Founded in 1998, the company has established itself as a trusted provider of high-quality solutions for cardiac and perfusion procedures. With a focus on quality, innovation, and patient care, the company continues to play a vital role in supporting critical care patients and advancing the field of cardiovascular medicine. Chalice Medical Inc. [email protected] SOURCE Chalice Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

$380,000 has been granted to 20 children's hospitals and health systems, as part of The Toy Foundation's Children's Hospital Play Grants program NEW YORK, March 5, 2024 /PRNewswire/ -- The Toy Foundation™, the philanthropic arm of The Toy Association™, is proud to announce $380,000 has been awarded to 20 children's hospitals and health systems that serve under-resourced communities, as part of its 2024 Childrens Hospital Play Grants program. More than 240,000 children in need will benefit from this initiative, which funds innovative play therapy projects proven to significantly improve care, wellbeing, and treatment outcomes of hospitalized children. Recent research shows that access to play elevates the overall patient experience by 98 percent¹. To provide play therapy projects to patients and better support their recovery, hospitals are reliant on external funding or donations to offer this key aspect of the holistic pediatric care model. The Toy Foundation's Children's Hospital Play Grants program helps fill this need at hospitals that need it most, where 50 percent or more of patients rely on Medicaid. The 2024 play projects funded by TTF include sensory toy stations, arts and crafts programs, and playroom and waiting area upgrades, among others, that the hospitals will complete by the end of the year. "Play has a profound impact on a child's healing journey during a hospital stay, providing physical, emotional, and educational benefits that you cannot get from medicine," said Pamela Mastrota, executive director at The Toy Foundation. "We are proud to expand the Play Grants program with a third annual distribution of grants that will support more hospitals and pediatric patients by giving them access to toys, art, and other play therapies to help improve children's coping skills and medical outcomes." 2024 Recipients of The Toy Foundation's Children's Hospital Play Grants include: Adventhealth Tampa - Tampa, FL Advocate Children's Hospital - Oak Brook, IL Arkansas Children's - Little Rock, AR Carilion Children's - Roanoke, VA Children's Specialized Hospital - Mountainside, NJ Children's Health Foundation - Oklahoma City, OK Children's Hospital at Montefiore - Bronx, NY CHRISTUS Children's - San Antonio, TX Covenant Children's Hospital - Saginaw, MI El Paso Children's Hospital Foundation - El Paso, TX Elizabeth Seton Children's Center - Yonkers, NY Joe DiMaggio Children's Hospital - Hollywood, FL Johns Hopkins All Children's Foundation – Saint Petersburg, FL La Rabida Children's Hospital - Chicago, IL Le Bonheur Children's Hospital - Memphis, TN Maimonides Medical Center - Brooklyn, NY MemorialCare Miller Children's & Women's Hospital Long Beach - Long Beach, CA Texas Children's Hospital - Houston, TX The Bernard & Millie Ducker Children's Hospital at Albany Medical Center - Albany, NY Valley Children's Hospital - Madera, CA The Children's Hospital Play Grants program has helped improve pediatric care for 360,000 children since 2021 through the funding of nearly 40 play projects at Children's Hospital Association member hospitals nationwide. Learn about the program's significant benefits to children in the 2022/2023 impact report. TTF is grateful for the generous partnership and financial support from Beacon Media Group and VTech Electronics North America. For more information about The Toy Foundation's Children's Hospital Play Grants program, visit ToyFoundation.org. About The Toy Foundation™ toyfoundation.org The Toy Foundation (TTF) is a 501 (c)(3) children's charity and philanthropic arm of The Toy Association™. As the uniting force for the collective philanthropy of the toy industry for the benefit of all children in need, TTF works with small, medium, and large companies to create a world where every child experiences the comfort, joy, and extraordinary physical, emotional, and educational benefits of play through three program areas – The Toy Bank℠, Play Grants, and Diversity, Equity, and Inclusion (DEI) Pipeline Program. Thanks to the toy industry's support, TTF has delivered play to more than 31 million children in need around the world. ¹ Source: Hope For Henry. (2024). SOURCE The Toy Foundation

– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater proportion of opioid-free patients receiving EXPAREL – TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the publication of its pivotal Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-dose sciatic nerve block in the popliteal fossa in patients undergoing bunionectomy. The results demonstrate that EXPAREL significantly improved pain control and reduced opioid consumption through 96 hours versus bupivacaine HCl. The data, which provided the basis for FDA approval for this indication was published in the Journal of Clinical Anesthesia. “This data provides unequivocal evidence of the safety and efficacy of EXPAREL as the first and only single-dose product to safely provide four days of superior non-opioid pain control compared to bupivacaine HCl,” said Frank D. Lee, Chief Executive Officer of Pacira BioSciences. “Importantly, the use of EXPAREL as a sciatic nerve block in the popliteal fossa affords clinicians additional flexibility in their opioid-sparing pain management approaches for foot and ankle procedures, which continue to migrate to the outpatient environment where success is predicated on the ability to provide appropriate pain control without the need for a significant opioid burden.” Key findings for EXPAREL 133 mg versus bupivacaine HCl 50 mg administered as a single-dose sciatic nerve block in the popliteal fossa for patients undergoing bunionectomy demonstrated statistically significant and superior pain control over bupivacaine for 4 days post-surgery: There was a 44% difference in pain scores through 96 hours—the study’s primary endpoint—as measured by the area under the curve, or AUC, of the Numerical Rating Scale pain intensity scores from 0 to 96 hours post-surgery; P<0.00001Patients receiving EXPAREL consumed 61% fewer opioids through 96 hours—the study’s secondary endpoint—LSM total opioid consumption; P<0.00001Almost one quarter of patients in the EXPAREL group needed no rescue opioids through 96 hours compared to the bupivacaine group (24.4% vs 6% of patients, respectively) Additionally, patients in the EXPAREL 133 mg arm had approximately five-fold higher odds of being opioid-free compared with the bupivacaine HCl 50 mg arm; P=0.0003 The safety profiles of EXPAREL 133 mg and bupivacaine HCl 50 mg were similar, with a similar proportion of adverse events (AEs) and serious adverse events (SAEs), and all AEs were mild to moderate in severity. “The role of EXPAREL as a sciatic nerve block in the popliteal fossa, particularly for pain control following foot and ankle procedures, is pivotal as clinical goals toward outpatient migration continue to grow,” said Gary Schwartz, MD, FASA, Vice Chair of Pain and Anesthesiology at Maimonides Medical Center and lead author on the publication. “The ability to deliver four days of pain control and reduce reliance on opioids with a single-administration—eliminating the burden of cumbersome catheters and pumps—provides not only a valuable addition to the pain management armamentarium, but also an opportunity to improve patient satisfaction and outcomes for same-day surgical procedures.” About the Phase 3 Study of EXPAREL as a Sciatic Nerve Block in the Popliteal FossaThe Phase 3, randomized, double-blind, active-controlled, multicenter study was designed to evaluate the efficacy, safety, and pharmacokinetics of EXPAREL versus bupivacaine HCl administered as a sciatic nerve block in the popliteal fossa. The study was conducted in two parts, with Part A completed and analyzed before enrollment in Part B was initiated. In total, the study randomized 185 subjects. In Part A, 66 subjects undergoing bunionectomy were randomized 1:1:1 to receive a sciatic nerve block in the popliteal fossa with a single dose of EXPAREL 266 mg, EXPAREL 133 mg or 20 mL 0.25% bupivacaine HCl. In part B, an additional 119 subjects undergoing bunionectomy were randomized 1:1 to receive a sciatic nerve block in the popliteal fossa with a single dose of EXPAREL 133 mg or 20 mL 0.25% bupivacaine HCl. All subjects in Part A and Part B received a Mayo field block with 20 mL 0.5% bupivacaine HCl after study drug administration in the operating room immediately prior to surgical incision. The study’s primary endpoint was the area under the curve, or AUC, of the Numerical Rating Scale pain intensity scores from 0 to 96 hours post-surgery comparing EXPAREL to bupivacaine HCl. Secondary endpoints included total postsurgical opioid consumption from 0 to 96 hours comparing EXPAREL to bupivacaine HCl and percent opioid free from 0-96 hours. About Pacira BioSciences Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com. About EXPAREL® EXPAREL (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com. Important Safety Information about EXPAREL for PatientsEXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder.